According to a recent LinkedIn post from Xeltis, the first implantation of its aXess vascular access conduit at Maastricht University Medical Center was completed last Thursday. The post notes that the procedure, performed by Dr. Maarten Snoeijs and his clinical team, was described as technically straightforward and compatible with standard surgical practice.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The company’s LinkedIn post highlights the presence of CEO Eliane Schutte and members of the clinical team at the procedure, underscoring the event’s internal significance. For investors, the post suggests incremental clinical progress for the aXess program, which could support future regulatory pathways and commercial prospects in vascular access solutions.
The characterization of the implantation as uneventful and easily integrated into routine surgery, if replicated in broader clinical experience, may strengthen Xeltis’s positioning versus existing graft technologies. While no financial metrics or timelines are mentioned, successful early clinical use at a university medical center could enhance credibility with clinicians and potential partners in the medtech and dialysis access markets.